Krystel El Hage

Has grant

Head of RNA Therapeutics Platform - Drug Discovery Program Lead

ThinQ Pharma

France

Research Interests

Explore related searches

Professors in France

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Krystel El Hage is the Head of the RNA Therapeutics Platform and Drug Discovery Program Lead at Qubit Pharmaceuticals, located in France. Her research focuses on RNA-targeted therapies and small molecule interactions, as evidenced by her recent publications on riboswitch inhibitors, RNA-protein interactions, and mRNA secondary structure dynamics. She employs advanced methodologies in her work, contributing to significant developments in the field of drug discovery and therapeutic innovations.

Recent Grants

Grant: Close

Molecules Inhibiting Translation in Cancer cells

Open Date:

Close Date:

Articles (10)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (3)

Jean-Philip Piquemal

Professor

Sorbonne Université

FRANCE

View details

Jérôme Hénin

CNRS

FRANCE

View details

Nohad Gresh

FRANCE

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Krystel El Hage

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (10)

Targeting RNA with small molecules using state-of-the-art methods provides highly predictive affinities of riboswitch inhibitors

Stabilization of a protein by a single halogen‐based aromatic amplifier

Lambda-ABF: Simplified, Portable, Accurate, and Cost-Effective Alchemical Free-Energy Computation

Enforcing Local DNA Kinks by Sequence‐Selective Trisintercalating Oligopeptides of a Tricationic Porphyrin: A Polarizable Molecular Dynamics Study**

Targeting RNA:protein interactions with an integrative approach leads to the identification of potent YBX1 inhibitors

Targeting the Major Groove of the Palindromic d(GGCGCC)<sub>2</sub>Sequence by Oligopeptide Derivatives of Anthraquinone Intercalators

Identification of a small molecule splicing inhibitor targeting UHM domains

YB-1 unwinds mRNA secondary structures in vitro and negatively regulates stress granule assembly in HeLa cells

The cooperative binding of TDP-43 to GU-rich RNA repeats antagonizes TDP-43 aggregation

Lin28, a major translation reprogramming factor, gains access to YB-1-packaged mRNA through its cold-shock domain

Collaborators (3)

Jean-Philip Piquemal

Jérôme Hénin

Nohad Gresh

Make your next move.